Search | Clinical Trials Finder

Conditions: Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
Interventions: HZN-825; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Miami, Florida + 8 more

Conditions: Scleroderma, Gastroparesis, Systemic Sclerosis (SSc)
Interventions: Transcutaneous Electrical Nerve Stimulation; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Interventions: ALLO-329, Cyclophosphamide, Fludarabine; Genetic · Drug
Lead sponsor: Allogene Therapeutics; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 13
States / cities: Phoenix, Arizona • Loma Linda, California • Aurora, Colorado + 10 more

Conditions: Refractory Lupus Nephritis, Refractory Systemic Sclerosis
Interventions: TAK-007, Chemotherapy Agents; Biological · Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diffuse Cutaneous Systemic Sclerosis
Interventions: IgPro10, Placebo; Biological
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Systemic Sclerosis, SSc
Interventions: Occupational therapy, Home app intervention; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Systemic Sclerosis-Associated PAH
Interventions: Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen; Biological · Other · Diagnostic Test + 1 more
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more

Conditions: Scleroderma, Interstitial Lung Disease
Interventions: dabigatran etexilate; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Infertility, Male, Cancer, Autoimmune Disorder
Interventions: Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic, Skin Diseases, Connective Tissue Diseases, Pathologic Processes, Autoimmune Diseases
Interventions: Oral Ifetroban, Oral Placebo; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Weston, Florida + 7 more

Conditions: Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
Interventions: Belimumab, Placebo; Biological · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 24
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more

Conditions: Scleroderma, Mildly Elevated Pulmonary Pressures
Interventions: Sildenafil, Placebo; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: New Orleans, Louisiana • Baltimore, Maryland

Conditions: Systemic Sclerosis (SSc), Scleroderma
Interventions: Tibulizumab, Placebo; Biological · Other
Lead sponsor: Zura Bio Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: La Jolla, California • Los Angeles, California • Plantation, Florida + 4 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD), Smoking, Smoking Cessation, Idiopathic Pulmonary Fibrosis (IPF), Rheumatoid Arthritis-Associated Interstitial Lung Disease, Scleroderma-Associated Interstitial Lung Disease (SSC-ILD)
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions: Alprostadil, Placebo; Drug · Other
Lead sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.); Industry
Eligibility: 18 Years to 79 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more

Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions: Temanogrel, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: New Haven, Connecticut • Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: Systemic Sclerosis-associated Interstitial Lung Disease
Interventions: Abituzumab 1500 mg, Abituzumab 500 mg, Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 18
States / cities: Los Angeles, California • Farmington, Connecticut • Washington D.C., District of Columbia + 12 more

Conditions: Lupus Nephritis, Autoimmune Diseases, Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathies, Stiff Person Syndrome
Interventions: ADI-001, Fludarabine, Cyclophosphamide; Drug
Lead sponsor: Adicet Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Redwood City, California • Buffalo, New York

Conditions: Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease
Interventions: Allogeneic NK Cells; Drug
Lead sponsor: Artiva Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 31
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions: Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 29
States / cities: Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more

Conditions: Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
Interventions: MEDI7734, Placebo; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 7
States / cities: Anniston, Alabama • Birmingham, Alabama • Danbury, Connecticut + 4 more

Conditions: Systemic Sclerosis
Interventions: RENEW; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Interstitial Lung Disease
Interventions: efzofitimod 450 mg, efzofitimod 270 mg, Placebo; Drug
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 10 more

Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease
Interventions: Tulisokibart, Companion diagnostic ( CDx), Placebo; Drug · Diagnostic Test
Lead sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 14 more

Search by objective public record fields.

An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)

TENS in Scleroderma

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis

Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma

Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Abituzumab in SSc-ILD

A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases

Self-Guided Resilience-Building Energy Management to Enhance Well-being (RENEW) Intervention for People With Systemic Sclerosis (SSc)

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)